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Abstract
Background: Bcl-2 is positively regulated by hormonal receptor pathways in breast cancer. A
study was conducted to assess the prognostic significances of clinico-pathologic variables and of ER,
PR, p53, c-erbB2, bcl-2, or Ki-67 as markers of relapse in breast cancer patients who had received
the identical adjuvant therapy at a single institution.
Methods: A cohort of 151 curatively resected stage III breast cancer patients (M:F = 3:148, median
age 46 years) who had 4 or more positive lymph nodes and received doxorubicin and
cyclophosphamide followed by paclitaxel (AC/T) as adjuvant chemotherapy was analyzed for
clinico-pathologic characteristics including disease-free survival (DFS) and overall survival (OS).
Patients with positive ER and/or PR expression received 5 years of tamoxifen following AC/T. The
protein expressions of biomarkers were assessed immunohistochemically.
Results: The median follow-up duration was 36 months, and 37 patients (24.5%) experienced a
recurrence. Univariate analyses indicated that the tumor size (P = 0.038) and the number of
involved lymph nodes (P < 0.001) significantly affected the recurrences. However, the type of
surgery, the histology, histologic grade, the presence of endolymphatic emboli, and a close
resection margin did not. Moreover, ER positivity (P = 0.013), bcl-2 positivity (P = 0.002) and low
p53 expression (P = 0.032) were found to be significantly associated with a prolonged DFS.
Furthermore, multivariate analysis identified 10 or more involved lymph nodes (HR 7.366; P <
0.001), negative bcl-2 expression (HR 2.895; P = 0.030), and c-erbB2 over-expression (HR 3.535;
P = 0.001) as independent indicators of poorer DFS. In addition, bcl-2 expression was found to be
significantly correlated with the expressions of ER and PR, and inversely correlated with the
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expressions of p53, c-erbB2 and Ki-67. Patients with bcl-2 expression had a significantly longer DFS
than those without, even in the ER (+) subgroup. Moreover, OS was significantly affected by ER,
bcl-2 and c-erbB2.
Conclusion: Bcl-2 is an independent prognostic factor of DFS in curatively resected stage III breast
cancer patients and appears to be a useful prognostic factor in combination with c-erbB2 and the
number of involved lymph nodes.
Background
Many therapeutic modalities have become available for
the treatment of breast cancer. As a consequence, interest
has grown for the delineation of prognostic markers iden-
tifying subsets of patients more likely to benefit from
adjuvant systemic therapies and for the development of
predictive markers for response to diverse treatments.
Adjuvant systemic chemotherapy reduces the risk of recur-
rence and death in breast cancer. Taxane-containing adju-
vant regimens have been reported to be more effective
than anthracycline-based regimens for curatively resected
node-positive breast cancer [1,2]. Doxorubicin/cyclo-
phosphamide followed by paclitaxel (AC/T) is generally
accepted as a standard for patients with node-positive
breast cancer [3,4].
Analyses of the usefulness of clinico-pathologic variables
as prognostic and predictive factors are clinically impor-
tant, but invariably imperfect. Hormonal receptor and C-
erbB2 expressions aid the selection of therapies, such as,
tamoxifen and trastuzumab, and are also used to select
adjuvant chemotherapies [5,6]. However, more accurate
and convenient markers are needed to identify patient
subgroups requiring individualized adjuvant chemother-
apy.
Most anticancer agents, independently of their mecha-
nisms of action, kill cancer cells by inducing apoptosis in
response to a drug-induced damage. Alterations in the reg-
ulatory mechanisms of apoptosis are, therefore, responsi-
ble not only for the progression of breast cancer, but for
different response to treatment as well [7].
Bcl-2 is a cytoplasmic protein belonging to the bcl-2 fam-
ily, is expressed in normal glandular epithelium, but it is
overexpressed in 25%–50% of breast cancers [8]. The bcl-
2 gene was initially identified in human B-cell lymphoma
because of its activity as an inhibitor of apoptosis in can-
cer cells. Other members of the bcl-2 family, such as bax,
also promote apoptosis [9]. As a consequence, the expres-
sion of bcl-2 in cancer cells is thought to inhibit apoptosis
and therefore relate to a worse outcome. However, the
expression of bcl-2 in breast cancer has been found to be
associated with favorable prognostic factors such as
smaller tumor size, ER positivity, and low nuclear grade.
Bcl-2 also predicts a more favorable outcome in metastatic
disease as well as in early breast cancer patients who
received heterogeneous adjuvant chemo- and hormonal
therapies [10-13]. One possible explanation is that the
acquisition of bcl-2 expression creates a restrictive envi-
ronment for the expansion of genetically unstable and
potentially malignant p53-deficient cells, causing a delay
in tumor progression and explaining the different prog-
nostic value of bcl-2 and p53 [14]. In addition, bcl-2 is
known to be up-regulated by estrogen and to be down-
regulated by p53 [15,16]. However, reports are contradic-
tory concerning whether bcl-2 is an independent predic-
tive marker for responses to primary chemotherapy [17].
In the present study, immunohistochemical staining was
used to determine the prognostic significance of ER, PR,
p53, c-erbB2, bcl-2, and Ki-67 expression in a homoge-
nous patient cohort who received AC/T as adjuvant ther-
apy for stage III breast cancer at a single institution.
Methods
Patients and treatment
Patients meeting the following characteristics were chosen
from electronically archived medical records: (1) Curative
resection of breast cancer at Seoul National University
Hospital, Korea between 1999 and 2004; (2) Pathologi-
cally determined involvement of 4 or more lymph nodes;
(3) The administration of AC/T as an adjuvant chemo-
therapy; (4) No trastuzumab adjuvant therapy; and (5)
Sufficient tissue samples available for immunohistochem-
ical analysis.
Adjuvant chemotherapy consisted of 60 mg/m2 doxoru-
bicin and 600 mg/m2 cyclophosphamide every 3 weeks
for 4 cycles followed by 175 mg/m2 paclitaxel every 3
weeks for 4 cycles [3]. Adjuvant radiotherapy or hormonal
therapy was performed as appropriate.
One hundred and fifty one patients, including 3 male
patients, met these inclusion criteria and were included in
this study. Patients with stage IIIB disease (T4 by AJCC
staging) were not included in this study, because these
patients were treated with a neoadjuvant chemotherapy
protocol. Thus, all 151 patients were at stage IIIA or IIIC
disease. Surgical treatment was radical modified mastec-
tomy, without removal of the pectoralis muscles, in 120
cases (79.5%) and breast conserving surgery includingBMC Cancer 2007, 7:63 http://www.biomedcentral.com/1471-2407/7/63
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quadrantectomy in 31 cases (20.5%). A level II axillary
dissection was performed in all patients and the mean
number of lymph nodes removed was 22.9 (range 7–54).
Of the 151 patients, 89 (58.9%) were ER and/or PR posi-
tive, and 87 (97.8%) of these patients received 5 years of
adjuvant tamoxifen. Thirty-one patients received breast-
conserving surgery and all, except one lost to follow-up,
received adjuvant radiotherapy. Of the 120 patients who
underwent modified radical mastectomy, 108 received
adjuvant radiotherapy. Patient characteristics are listed in
Table 1.
Pathologic Examination and Immunohistochemistry
Primary tumor specimens were paraffin-embedded after
surgery. Standard histopathological examination
included the type of cancer, the pathological tumor stage
assessed according to the criteria established by the 6th
edition of AJCC cancer staging manual [18], the grade of
the tumor according to the Scarff-Bloom-Richardson
(SBR) classification modified by Elston and Ellis [19], and
the presence of endolymphatic emboli.
The routinely formalin-fixed, paraffin-embedded tissue
blocks were sectioned at 4- µm thickness and then proc-
essed for immunohistochemistry. Tissue sections were
deparaffinized in xylene, rehydrated with graded ethanol,
and immersed in Tris-buffered saline. After an antigen-
retrieval process, representative sections were immunos-
tained and more than 10 randomly chosen high power
fields were examined under an optical microscope.
The companies that supplied the primary antibodies and
the dilution factors used were; ER (Dako Corporation,
Carpinteria, CA; 1:50), PR (Dako Corporation; 1:50), p53
(Dako Corporation; 1:1200), c-erbB2 (Novocastra Labo-
ratories Ltd., New Castle-Upon-Tyne, U.K.; 1:200), bcl-2
(Dako Corporation; 1:50), and Ki-67 (Dako Corporation;
1:800). All primary antibodies were mouse monoclonal
antibodies. Biotinylated anti-mouse antibody was used as
secondary antibody and streptavidin horseradish peroxi-
dase (Zymed laboratories, San Francisco, CA) methods
were used following the instructions provided by the
manufacturer. Finally, the sections were counter-stained
in Mayer's hematoxylin, dehydrated, cleared, and
mounted for examination.
A cut-off value of 10% or more positively stained nuclei in
ten high-power fields was used to define ER and PR posi-
tivity. Only cytoplasmic staining was scored as positive for
bcl-2, regardless of the intensity of the stained cells. Mem-
branous staining for C-erbB2 was scored as: 0, faint
incomplete staining in 10% or less of cells; 1, faint incom-
plete staining in more than 10% of cells; 2, weak to mod-
erate complete staining in more than 10% of cells; 3,
strong complete staining in more than 10% of cells. Cells
stained for Ki-67 were counted and expressed as percent-
ages, and the number of cells stained for p53 were scored
semi-quantitatively, as follows; 0%, 1–25%, 26–50%, 51–
75%, or > 75%.
Statistical analysis
Statistical analyses of categorical variables were performed
using Pearson's χ2 test or Fisher's exact test as appropriate.
Disease free survival (DFS) was calculated from the date of
surgery to the first observation of disease recurrence, and
overall survival (OS) from the date of surgery to the date
of death or the date when the patient was last known to be
alive. The median durations of DFS and OS were calcu-
lated using the Kaplan-Meier method. Comparisons
between groups were made using log-rank tests. Multivar-
iate analysis was carried out using the Cox proportional
hazards model. A significance level of 0.20 was used for
Table 1: Clinicopathologic characteristics of 151 patients
Pt. number %
Sex M 3 2.0%
F 148 98.0%
Age median 46 years range 28–70 years
≤50 111 73.5%
> 50 40 26.5%
Surgery MRM 120 79.5%
BCS 31 20.5%
Histology ductal 138 91.4%
others 13 8.6%
Stage IIIA 79 52.3%
IIIC 72 47.7%
Tumor size pT ≤ 2 cm 11 7.3%
2 < pT ≤ 5 110 72.8%
pT > 5 cm 30 19.9%
Involved LNs 4–9 79 52.3%
≥10 72 47.7%BMC Cancer 2007, 7:63 http://www.biomedcentral.com/1471-2407/7/63
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covariate entry. Two-sided P values of < 0.05 were consid-
ered significant. All analyses were performed using SPSS
for Windows, version 12.0 (SPSS Inc, Chicago, IL).
Ethics
The study protocol was reviewed and approved by the
institutional review board of Seoul National University
Hospital, and complied with the recommendations of the
Declaration of Helsinki for biomedical research involving
human subjects.
Results
Patient characteristics
Baseline patient characteristics are presented in Table 1.
The median follow-up duration for the 151 patients was
36 months (range 8–78). Thirty-seven (24.5%) patients
experienced breast cancer recurrence, and 34 of these had
distant metastases. Frequent sites of distant metastases
were bone in 17 patients, lung in 11, liver in 7, and brain
in 2.
Expressions of markers and their inter-associations
Immunohistochemical results were obtained for 151
patients. ER was positive in 83 (55.0%), PR in 59
(39.1%), and bcl-2 in 92 (60.9%). P53 was expressed in
more than 25% of the tumor cells in 46 patients (30.5%);
C-erbB2 was 3+ in 30 patients (19.9%); and Ki-67 was 5%
or more in 56 patients (37.1%). Details are shown in
Table 2.
The relationships between bcl-2 and the other markers
were evaluated. Ninety two % (76 of 83) of the tumors
showing ER expression co – expressed bcl-2, and bcl-2
expression was found to be correlated with PR expression.
However, p53 (> 25%), c-erbB2 (3+), and Ki-67 (= 5%)
expression were found to be inversely correlated with bcl-
2. In addition, bcl-2 (-) tumors were significantly corre-
lated with the histologic grade III. Details are shown in
Table 3.
Univariate analysis: clinicopathological factors and 
molecular markers
Tumor size (3 yr DFS, 78.6% for < 5 cm vs. 42.3% for = 5
cm, P = 0.038) and the number of involved lymph nodes
(3 yr DFS, 89.8% for 4–9 nodes vs. 52.7% for = 10 nodes,
P < 0.001) significantly affected recurrence, but the type of
surgery, the histology, histologic grade, the presence of
endolymphatic emboli, and a close resection margin < 2
mm did not.
Of the molecular markers, ER (3 yr DFS, 77.2% for ER (+)
vs. 64.9% for ER (-), P = 0.013), bcl-2 (3 yr DFS, 77.6% for
bcl-2 (+) vs. 62.0% for bcl-2 (-), P = 0.002) and p53 (3 yr
DFS, 75.5% for p53 = 25% vs. 62.1% for p53 > 25%, P =
0.032) were found to be significantly related to DFS, but
PR, c-erbB2, and Ki-67 were not.
OS was found to be significantly related to the number of
involved lymph nodes (3 yr OS, 100% for 4–9 nodes vs.
83.7% for = 10 nodes, P < 0.001) and histologic grade (3
yr OS, 98.4% for histologic grade I, II vs. 84.3% for III, P
= 0.043).
ER (3 yr OS, 100% for ER (+) vs. 83.4% for ER (-), P =
0.006), bcl-2 (3 yr OS, 97.4% for bcl-2 (+) vs. 83.9% for
bcl-2 (-), P = 0.009) and c-erbB2 (3 yr OS, 79.6% for c-
erbB2 (3+) vs. 96.3% for c-erbB2 (-) to (2+), P < 0.001)
were significantly correlated with OS (Table 4, Figure 1).
Multivariate analysis for DFS
Multivariate analysis was performed for DFS using tumor
size, number of lymph nodes, ER, PR, bcl-2, p53, c-erbB2,
and Ki-67 as covariates. Ten or more lymph nodes (HR
7.366; p < 0.001), negative bcl-2 expression (HR 2.895; p
= 0.033), and c-erbB2 over-expression (HR 3.535; p =
0.002) were identified as independent indicators of a
shorter DFS.
DFS according to bcl-2 status in ER (+) and ER (-) 
subgroups
Because bcl-2 was found to be strongly correlated with ER
expression, ER (+) and ER (-) subgroups were analyzed
separately for DFS according to bcl-2 status. In 83 patients
with ER (+) tumors, 7 patients had tumors not expressing
bcl-2 and these patients had a significantly shorter DFS.
However, in the ER (-) subgroup no significant differences
were found on DFS according to bcl-2 status (Figure 2).
Discussion
The identification of prognostic and predictive markers is
clinically important, because breast cancer is a group of
heterogenous diseases with various biological and clinical
characteristics. ER and PR, as determined by IHC, have
been used as predictive markers for hormonal therapy and
prognostic factors. C-erbB2 status, as determined by IHC
or FISH, indicates poorer survival. Possible benefits may
be derived by therapeutically targeting these molecules.
Recently, gene expression microarray studies have shown
a strong prognostic power [20-22], but immunohisto-
chemistry remains a convenient and powerful means of
prognostication in a clinical setting as it is less expensive
and easier to perform.
The present study highlights the importance of bcl-2 in
breast cancer in a homogenous patient cohort. This role as
an independent prognostic factor of DFS is in addition to
the known prognostic factors c-erbB2 and the number of
involved lymph nodes. This observation is in accordance
with previous reports [10-12], and further validates theBMC Cancer 2007, 7:63 http://www.biomedcentral.com/1471-2407/7/63
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role of bcl-2 as an independent prognostic marker. How-
ever, the present study is the first to evaluate bcl-2 in high-
risk patients with stage III breast cancer treated with a
homogenous adjuvant regimen, i.e., AC/T. Tsutsui et al
[13] recently reported that decreased bcl-2 expression is
associated with a poorer disease free survival by an univar-
iate analysis but loses its statistical significances in a mul-
tivariate analysis if proliferation activity as represented by
MIB-1 counts was used as a covariate. The prognostic
importance of bcl-2 in the present study is also in agree-
ment with that of Tsutsui et al [13], but is further vali-
dated, by the multivariate analysis. Bcl-2 is a prognostic
marker independent of the proliferation marker, Ki-67,
possibly because of the homogeneity of the patients with
4 or more positive lymph nodes (Table 5). In addition,
bcl-2 was identified in another study as a prognostic
marker independent of the Nottingham prognostic index
in 930 cases of mainly node-negative breast cancer with a
longer follow-up period [12]. The present study reports
similar results in more advanced cases with 4 or more pos-
itive lymph nodes with a shorter follow-up period.
Because bcl-2 blocks apoptosis in vitro, and thus contrib-
utes to malignant cell accumulation, its over-expression is
expected to be associated with more aggressive tumor
biology. Indeed, genetic alteration of the bcl-2 gene
Table 2: Molecular characteristics of the tumors
Pt. number %
ER (-) 68 45.0
(+) 83 55.0
PR (-) 92 60.9
(+) 59 39.1
bcl-2 (-) 59 39.1
(+) 92 60.9
p53 0 47 31.1
1–25% 58 38.4
26–50% 11 7.3
51–75% 8 5.3
76–100% 27 17.9
c-erbB2 0 65 43.0
+3 6 2 3 . 8
++ 20 13.2
+++ 30 19.9
Ki-67 < 5% 67 44.4
≥5% 84 55.6
Table 3: The association between bcl-2 and other markers
Bcl-2 expression P
(-) (+)
Histology ductal 55 (39.9) 83 (60.1) 0.521
others 4 (30.8) 9 (69.2)
Histologic grade I, II 14 (21.2) 52 (78.8) < 0.001
III 42 (54.5) 35 (45.5)
Endolymphatic tumor 
emboli
absent 2 (33.3) 4 (66.7) 1.000
present 43 (37.1) 73 (62.9)
ER (-) 52 (76.5) 16 (23.5) < 0.001
(+) 7 (8.4) 76 (91.6)
PR (-) 55 (59.8) 37 (40.2) < 0.001
(+) 4 (6.8) 55 (93.2)
p53 ≤25% 33 (31.4) 72 (68.6) 0.004
>25% 26 (56.5) 20 (43.5)
c-erbB2 (-)~(2+) 42 (34.7) 79 (65.3) 0.027
(3+) 17 (56.7) 13 (43.3)
Ki-67 < 5% 18 (26.9) 49 (73.1) 0.006
≥5% 41 (48.8) 43 (51.2)
n (%) patients for each variable. P-values were obtained using the chi-square test.BMC Cancer 2007, 7:63 http://www.biomedcentral.com/1471-2407/7/63
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located on chromosome 18 is considered to be a key proc-
ess in the pathogenesis and chemoresistance of human
tumors, such as follicular lymphoma [23]. However, in
breast cancer specimens, bcl-2 expression is associated
with markers of better differentiation, like lower grade
lesions, ER positivity, and a low proliferation status [24].
These aspects of bcl-2 are reproduced in the present study.
In the present study, bcl-2 was identified as an independ-
ent marker of DFS by multivariate analysis when other
associated factors were used as covariates. Tumors express-
ing ER are considered more indolent, as exemplified by
'luminal tumors' in gene expression microarray studies
[20-22]. In the present study, bcl-2 was found to be a
stronger predictor of DFS than ER expression, as shown in
Table 4, and ER (+), bcl-2 (-) patients were observed to
have a shorter DFS than ER (+), bcl-2 (+) patients. These
results suggest the important role of bcl-2 expression inde-
pendently of hormonal receptor markers.
However, whether bcl-2 is a predictive marker of benefit
from the specific adjuvant chemotherapy AC/T, which
contains paclitaxel, is not clear. This was difficult to deter-
mine in our cohort which included patients treated with a
single regimen containing paclitaxel but not controls. Bcl-
2 was not found to have any predictive value in terms of
response to a single cycle of perioperative 5-FU/doxoru-
bicin/cyclophosphamide chemotherapy in a previous
study of 423 patients [8]. A small number of preclinical
reports are available regarding taxane chemosensitivity
and bcl-2 protein expression. Bcl-2 expression was found
to be related to a response to paclitaxel in human non-
small cell lung cancer tumors heterotransplanted into
nude mice [25]. Positive bcl-2 expression was found to be
significantly associated with enhanced docetaxel sensitiv-
ity in vitro in non-small cell lung cancer [26]. Moreover,
bcl-2 down-regulation has been associated with paclitaxel
resistance [27]. These preclinical findings suggest the pos-
sibility that bcl-2 is a predictive marker of response to
paclitaxel, and this possibility requires further evaluation.
In the present study, C-erbB2, also called HER2, as is bcl-
2 was found to be an independent predictor of a shorter
DFS. C-erbB2 amplification is known to be associated
with clinical responsiveness to anthracycline-containing
chemotherapy [28,29]. Furthermore, the CALGB 9344
trial, which demonstrated improved outcomes for AC/T,
showed that the benefit of adding paclitaxel to AC is
greater for C-erbB2 (+) tumors, whereas paclitaxel showed
no apparent benefit in the ER (+), c-erbB2 (-) group
[3,30], which suggests the efficacy of paclitaxel against c-
erbB2 (+) tumors. In the present study, c-erbB2 over-
expression indicated a poorer outcome, despite the use of
Table 4: Univariate analyses of clinicopathological factors and molecular markers
Number 3 yr DFS P 3 yr OS P
Tumor size < 5 cm
≥5 cm
121
30
78.6%
42.3%
0.038 92.1%
91.1%
0.952
Number of lymph nodes 4–9
≥10
79
72
89.8%
52.7%
< 0.001 100%
83.7%
0.001
Surgery MRM
BCS
120
31
70.0%
79.0%
0.808 90.9%
96.3%
0.953
Histology Ductal
Others
138
13
71.1%
76.9%
0.461 91.0%
100.0%
0.323
Histologic grade I, II
III
65
76
74.7%
69.5%
0.160 98.4%
84.3%
0.043
Endolymphatic tumor emboli absent
present
5
116
55.6%
71.7%
0.459 100%
91.6%
0.490
Close RM ≤2 mm
> 2 mm
5
146
70.8%
80.0%
0.590 91.5%
100%
0.475
ER (-)
(+)
68
83
64.9%
77.2%
0.013 83.4%
100%
0.006
PR (-)
(+)
92
59
68.3%
76.2%
0.136 87.1%
100%
0.121
p53 ≤25%
>25%
105
46
75.5%
62.1%
0.032 93.8%
87.8%
0.213
bcl-2 (-)
(+)
59
92
62.0%
77.6%
0.002 83.9%
97.4%
0.009
c-erbB2 (-) to (2+)
(3+)
121
30
74.3%
60.6%
0.112 96.3%
79.6%
0.050
Ki-67 < 5%
≥5%
94
56
85.6%
61.8%
0.146 91.0%
92.4%
0.631BMC Cancer 2007, 7:63 http://www.biomedcentral.com/1471-2407/7/63
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two active chemotherapeutic agents, doxorubicin and
paclitaxel. Patients treated with adjuvant trastuzumab
were not included in this study, and thus the effects of this
targeting agent were excluded.
Conclusion
We conclude that bcl-2, and the known prognostic factors
c-erbB2 and the number of involved lymph nodes are
independent prognostic factors of DFS in curatively
resected stage III breast cancer patients, and that molecu-
lar marker analysis is useful to discriminate subsets of
patient with different prognoses.
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Kaplan-Meier plots of (A) disease-free and (B) overall survival according to bcl-2 expression Figure 1
Kaplan-Meier plots of (A) disease-free and (B) overall survival according to bcl-2 expression. The expression of bcl-2 was found 
to be significantly and positively associated with disease-free and overall survivals.
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Disease-free survival according to bcl-2 status in (A) ER-positive and (B) ER-negative pateints Figure 2
Disease-free survival according to bcl-2 status in (A) ER-positive and (B) ER-negative pateints. Bcl-2 (+) patients showed better 
disease-free survival even in those with an ER (+) status, suggesting that bcl-2 has a prognostic role that is independent of ER 
expression.
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Table 5: Multivariate analysis for disease free survival
HR 95% CI P-value
tumor size (≥ 5 cm) 1.260 (0.602, 2.637) 0.539
number of lymph nodes (≥ 10) 7.366 (2.982, 18.197) < 0.001
ER (-) 0.988 (0.316, 3.089) 0.984
PR (-) 0.717 (0.254, 2.025) 0.530
bcl-2 (-) 2.895 (1.090, 7.690) 0.033
p53 (> 25%) 1.065 (0.507, 2.237) 0.868
c-erbB2 (3+) 3.535 (1.616, 7.731) 0.002
Ki-67 (≥ 5%) 1.247 (0.614, 2.534) 0.541BMC Cancer 2007, 7:63 http://www.biomedcentral.com/1471-2407/7/63
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